Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1997 Nov;77(5):389–391. doi: 10.1136/adc.77.5.389

Targeted radiotherapy for neuroblastoma

S MELLER 1
PMCID: PMC1717381  PMID: 9487957

Full Text

The Full Text of this article is available as a PDF (83.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armour A., Cunningham S. H., Gaze M. N., Wheldon T. E., Mairs R. J. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Br J Cancer. 1997;75(4):470–476. doi: 10.1038/bjc.1997.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beierwaltes W. H., Nishiyama R. H., Thompson N. W., Copp J. E., Kubo A. Survival time and "cure" in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy. J Nucl Med. 1982 Jul;23(7):561–568. [PubMed] [Google Scholar]
  3. Cheung N. K., Lazarus H., Miraldi F. D., Abramowsky C. R., Kallick S., Saarinen U. M., Spitzer T., Strandjord S. E., Coccia P. F., Berger N. A. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987 Sep;5(9):1430–1440. doi: 10.1200/JCO.1987.5.9.1430. [DOI] [PubMed] [Google Scholar]
  4. Clerc J., Halpern S., Fourré C., Omri F., Briançon C., Jeusset J., Fragu P. SIMS microscopy imaging of the intratumor biodistribution of metaiodobenzylguanidine in the human SK-N-SH neuroblastoma cell line xenografted into nude mice. J Nucl Med. 1993 Sep;34(9):1565–1570. [PubMed] [Google Scholar]
  5. Corbett R., Pinkerton R., Tait D., Meller S. [131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma. J Nucl Biol Med. 1991 Oct-Dec;35(4):228–231. [PubMed] [Google Scholar]
  6. De Kraker J., Hoefnagel C. A., Caron H., Valdés Olmos R. A., Zsiros J., Heij H. A., Voûte P. A. First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer. 1995;31A(4):600–602. doi: 10.1016/0959-8049(95)00063-o. [DOI] [PubMed] [Google Scholar]
  7. Deacon J. M., Wilson P. A., Peckham M. J. The radiobiology of human neuroblastoma. Radiother Oncol. 1985 Apr;3(3):201–209. doi: 10.1016/s0167-8140(85)80029-3. [DOI] [PubMed] [Google Scholar]
  8. Gaze M. N., Mairs R. J., Boyack S. M., Wheldon T. E., Barrett A. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer. 1992 Dec;66(6):1048–1052. doi: 10.1038/bjc.1992.408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gaze M. N., Mairs R. J., Vaidyanathan G., Zalutsky M. R. Synthesis of carrier-free 131I-meta-iodobenzyl-guanidine by novel routes to enhance therapeutic efficiency in neuroblastoma. Prog Clin Biol Res. 1994;385:347–353. [PubMed] [Google Scholar]
  10. Gaze M. N., Wheldon T. E., O'Donoghue J. A., Hilditch T. E., McNee S. G., Simpson E., Barrett A. Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer. 1995;31A(2):252–256. doi: 10.1016/0959-8049(94)e0036-4. [DOI] [PubMed] [Google Scholar]
  11. Hoefnagel C. A., de Kraker J., Voûte P. A., Valdés Olmos R. A. Preoperative [131I]metaiodobenzylguanidine therapy of neuroblastoma at diagnosis ("MIBG de novo"). J Nucl Biol Med. 1991 Oct-Dec;35(4):248–251. [PubMed] [Google Scholar]
  12. Kimmig B., Brandeis W. E., Eisenhut M., Bubeck B., Hermann H. J., zum Winkel K. Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine. J Nucl Med. 1984 Jul;25(7):773–775. [PubMed] [Google Scholar]
  13. Klingebiel T., Berthold F., Treuner J., Schwabe D., Fischer M., Feine U., Maul F. D., Waters W., Wehinger H., Niethammer D. Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial. Med Pediatr Oncol. 1991;19(2):84–88. doi: 10.1002/mpo.2950190203. [DOI] [PubMed] [Google Scholar]
  14. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  15. Ladenstein R., Lasset C., Hartmann O., Frappaz D., Garaventa A., Klingebiel T., Zucker J. M., Coze C., Burdach S., Gadner H. Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation. J Clin Oncol. 1993 Dec;11(12):2330–2341. doi: 10.1200/JCO.1993.11.12.2330. [DOI] [PubMed] [Google Scholar]
  16. Lashford L. S., Clarke J., Kemshead J. T. Systemic administration of radionuclides in neuroblastoma as planned radiotherapeutic intervention. Med Pediatr Oncol. 1990;18(1):30–36. doi: 10.1002/mpo.2950180107. [DOI] [PubMed] [Google Scholar]
  17. Lashford L. S., Lewis I. J., Fielding S. L., Flower M. A., Meller S., Kemshead J. T., Ackery D. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol. 1992 Dec;10(12):1889–1896. doi: 10.1200/JCO.1992.10.12.1889. [DOI] [PubMed] [Google Scholar]
  18. Mairs R. J., Russell J., Cunningham S., O'Donoghue J. A., Gaze M. N., Owens J., Vaidyanathan G., Zalutsky M. R. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. Eur J Cancer. 1995;31A(4):576–581. doi: 10.1016/0959-8049(95)00052-k. [DOI] [PubMed] [Google Scholar]
  19. Mastrangelo R., Tornesello A., Riccardi R., Lasorella A., Mastrangelo S., Mancini A., Rufini V., Troncone L. A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer. 1995;31A(4):606–611. doi: 10.1016/0959-8049(95)00048-n. [DOI] [PubMed] [Google Scholar]
  20. Montaldo P. G., Carbone R., Ponzoni M., Cornaglia-Ferraris P. gamma-Interferon increases metaiodobenzylguanidine incorporation and retention in human neuroblastoma cells. Cancer Res. 1992 Sep 15;52(18):4960–4964. [PubMed] [Google Scholar]
  21. Moyes J. S., Babich J. W., Carter R., Meller S. T., Agrawal M., McElwain T. J. Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with neuroblastoma: correlation with tumor histopathology. J Nucl Med. 1989 Apr;30(4):474–480. [PubMed] [Google Scholar]
  22. Muggia F. M., Glatstein E. Summary of investigations on platinum compounds and radiation interactions. Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1407–1409. doi: 10.1016/0360-3016(79)90679-5. [DOI] [PubMed] [Google Scholar]
  23. O'Donoghue J. A., Wheldon T. E., Babich J. W., Moyes J. S., Barrett A., Meller S. T. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma. Br J Radiol. 1991 May;64(761):428–434. doi: 10.1259/0007-1285-64-761-428. [DOI] [PubMed] [Google Scholar]
  24. Order S. E. Systemic radiotherapy--the new frontier. Int J Radiat Oncol Biol Phys. 1990 May;18(5):981–992. doi: 10.1016/0360-3016(90)90431-i. [DOI] [PubMed] [Google Scholar]
  25. Picco P., Garaventa A., Claudiani F., Gattorno M., De Bernardi B., Borrone C. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma. Cancer. 1995 Nov 1;76(9):1662–1664. doi: 10.1002/1097-0142(19951101)76:9<1662::aid-cncr2820760924>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  26. Pizer B., Papanastassiou V., Hancock J., Cassano W., Coakham H., Kemshead J. A pilot study of monoclonal antibody targeted radiotherapy in the treatment of central nervous system leukaemia in children. Br J Haematol. 1991 Apr;77(4):466–472. doi: 10.1111/j.1365-2141.1991.tb08611.x. [DOI] [PubMed] [Google Scholar]
  27. Sisson J. C., Frager M. S., Valk T. W., Gross M. D., Swanson D. P., Wieland D. M., Tobes M. C., Beierwaltes W. H., Thompson N. W. Scintigraphic localization of pheochromocytoma. N Engl J Med. 1981 Jul 2;305(1):12–17. doi: 10.1056/NEJM198107023050103. [DOI] [PubMed] [Google Scholar]
  28. Sisson J. C., Hutchinson R. J., Carey J. E., Shapiro B., Johnson J. W., Mallette S. A., Wieland D. M. Toxicity from treatment of neuroblastoma with 131I-meta-iodobenzylguanidine. Eur J Nucl Med. 1988;14(7-8):337–340. doi: 10.1007/BF00254379. [DOI] [PubMed] [Google Scholar]
  29. Sisson J. C., Hutchinson R. J., Shapiro B., Zasadny K. R., Normolle D., Wieland D. M., Wahl R. L., Singer D. A., Mallette S. A., Mudgett E. E. Iodine-125-MIBG to treat neuroblastoma: preliminary report. J Nucl Med. 1990 Sep;31(9):1479–1485. [PubMed] [Google Scholar]
  30. Smets L. A., Janssen M., Rutgers M., Ritzen K., Buttenhuis C. Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells. Int J Cancer. 1991 Jun 19;48(4):609–615. doi: 10.1002/ijc.2910480421. [DOI] [PubMed] [Google Scholar]
  31. Smets L. A., Loesberg C., Janssen M., Metwally E. A., Huiskamp R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res. 1989 Jun 1;49(11):2941–2944. [PubMed] [Google Scholar]
  32. Strickland D. K., Vaidyanathan G., Zalutsky M. R. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res. 1994 Oct 15;54(20):5414–5419. [PubMed] [Google Scholar]
  33. The role of [131I]Metaiodobenzylguanidine in the treatment of neural crest tumors. Proceedings of an international workshop. Rome, Italy, September 6-7, 1991. J Nucl Biol Med. 1991 Oct-Dec;35(4):177–363. [PubMed] [Google Scholar]
  34. Tobes M. C., Jaques S., Jr, Wieland D. M., Sisson J. C. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med. 1985 Aug;26(8):897–907. [PubMed] [Google Scholar]
  35. Vaidyanathan G., Zalutsky M. R. Targeted therapy using alpha emitters. Phys Med Biol. 1996 Oct;41(10):1915–1931. doi: 10.1088/0031-9155/41/10/005. [DOI] [PubMed] [Google Scholar]
  36. Voûte P. A., Hoefnagel C. A., de Kraker J., Valdes Olmos R., Bakker D. J., van de Kleij A. J. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. Prog Clin Biol Res. 1991;366:439–445. [PubMed] [Google Scholar]
  37. Wafelman A. R., Hoefnagel C. A., Maes R. A., Beijnen J. H. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med. 1994 Jun;21(6):545–559. doi: 10.1007/BF00173043. [DOI] [PubMed] [Google Scholar]
  38. Wieland D. M., Swanson D. P., Brown L. E., Beierwaltes W. H. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J Nucl Med. 1979 Feb;20(2):155–158. [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES